IDWeek 2019
AWG Member Company Participation at IDWeek 2019
Eleven AWG member companies presented data from their clinical and research programs at IDWeek 2019 held October 2-6 in Washington, DC. Representatives from AWG member companies presented a total of 51 poster presentations and one oral abstract presentation.
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS) that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
Thursday, October 3rd
Poster Abstract Session: 037. Bacteremia, CLABSI, and Endovascular Infections
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Paratek Pharmaceuticals
- #110 – Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
Poster Abstract Session: 051. Soft Tissue and Skin Infections
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Melinta Therapeutics:
- #443 – The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin For Treatment of Gram-positive Infections
- #470 – Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)
Poster Abstract Session: 068. Novel Antimicrobials and Approaches Against Resistant Bugs
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Amplyx Pharmaceuticals:
- #678 – Galactomannan is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosi
- #726 – APX001 (Fosmanogepix) is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
Aridis Pharmaceuticals:
- #674 – Pre-Clinical and Phase I Safety Data for Anti-Pseudomonas aeruginosa Human Monoclonal Antibody AR-105
- #716 – In Vitro and In Vivo Non Clinical Efficacy of AR-501 (Gallium Citrate)
Cidara Therapeutics:
- #689 – Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria)
Entasis Therapeutics:
- #694 – In vitro Antibacterial Activity of Sulbactam-Durlobactam (ETX2514SUL) against 121 Recent Acinetobacter baumannii Isolated from Patients in India
- #709 – In vitro Antibacterial Activity and in vivo Efficacy of Sulbactam-Durlobactam (ETX2514SUL) against Pathogenic Burkholderia Species
Melinta Therapeutics:
- #662 – Recurrence of infection and emergence of drug resistance after treatment with meropenem/vaborbactam compared to ceftazidime/avibactam in carbapenem-resistant Enterobacteriaceae infections
Nabriva Therapeutics:
- #663 – Efficacy and Safety of Lefamulin (LEF) Versus Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients (Pts) With Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials
- #664 – Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes
- #676 – Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2)
- #684 – Cardiac Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
- #699 – Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
- #703 – In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)
- #705 – Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis
- #717 – Lefamulin (LEF) Versus Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials
- #720 – Efficacy of Fosfomycin for Injection (FOS) vs Piperacillin-Tazobactam (PIP-TAZ) in Adults With Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): ZEUS Study Outcomes in Patients With Reduced Study Drug Susceptibility
- #722 – Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function
Paratek Pharmaceuticals:
- #665 – In Vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections
- #700 – Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
- #733 – Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
- #734 – Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
Qpex Biopharma:
- #677 – Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates
- #681 – In vitro Activity of the β-lactamase Inhibitor QPX7728 in Combination wtih Several β-lactams against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA)
- #690 – Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, including Carbapenem-Resistant Acinetobacter, Enterobacterales, and Pseudomonas
- #707 – QPX9003: Pharmacology of a Novel Polymyxin in Mice and Rats
- #727 – Potency of the Beta-Lactamase Inhibitor QPX7728 Is Minimally Affected by KPC Mutations that Reduce Potency of Ceftazidime-Avibactam
SCYNEXIS:
- #672 – Activity of Ibrexafungerp (formerly SCY-078) Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia
- https://www.eventscribe.com/2019/IDWeek/ajaxcalls/PosterInfo.asp?efp=Q0NRVktHSkw2ODg2&PosterID=230670&rnd=0.3133847
Summit Therapeutics:
- #668 – Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN)
VenatoRx Pharmaceuticals:
- #682 – In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model when Administered in Combination with Humanized Exposures of Twice Daily Ceftibuten (CTB) against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB)
Rapid Fire Poster Session: Antimicrobial Resistance
Time: 12:15pm – 12:45pm ET
Location: Hall B + C – Arena 2
Melinta Therapeutics:
12:20pm – 12:25pm ET
- #100 – Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared to Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
Friday, October 4
Poster Abstract Session: 156. Osteomyelitis
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Melinta Therapeutics:
- #1420 – Successful Treatment of Acute Osteomyelitis with Once Weekly Oritavancin
Poster Abstract Session: 157. Urinary Tract Infections
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Nabriva Therapeutics:
- #1440 – Prevalence and Regional Variation of in ESBLs and CRE Enterobacteriaceae (ENT) among Adult, Hospitalized Patients with ENT on a Urine Culture: A Multicenter Evaluation
- #1485 – Trends in Important Resistant Gram-negative (GN) and Gram-positive (GP) Urine Bacterial Pathogens in Hospitalized Patients in the US: A Multicenter Evaluation from 2013-2018
Poster Abstract Session: 162. PK/PD and Susceptibility Testing
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Paratek Pharmaceuticals:
- #1561 – Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
Melinta Therapeutics:
- #1582 – Delafloxacin Activity against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014-2018)
- #1583 – Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin
- #1584 – Minocycline Activity against Stenotrophomonas maltophilia isolated from Patients in US Hospitals
- #1588 – Delafloxacin Activity against Staphylococcus aureus with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin or Linezolid
Saturday, October 5
Oral Abstract Session: A1. Novel Agents
Time: 11:15am – 1:00pm ET
Location: Room 144 ABC
Amplyx Pharmaceuticals:
11:15am – 11:30am ET
- #1954 – In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
Poster Abstract Session: 243. Bacterial Diagnostics
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Melinta Therapeutics:
- #2131 – Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae Using MicroScan Dried Gram Negative MIC Panels
Poster Abstract Session: 244. Bacterial Respiratory Infections
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Nabriva Therapeutics:
- #2233 – Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
Poster Abstract Session: 246. Clinical Outcomes of Infections with Resistant Organisms
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Nabriva Therapeutics:
- #2245 – Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community‑Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study
Poster Abstract Session: 267. Microbiome, Antibiotics, and Pathogenesis
Time: 12:15pm – 1:30pm ET
Location: Hall B + C
Summit Therapeutics:
- #2567 – Effect of broad vs. narrow spectrum Clostridioides difficile treatment on human stool bile acid composition over time
- #2578 – Narrow-spectrum antibiotic treatment of Clostridium difficile infection improves preservation of intestinal metabolic profile